Joe Ganley

home / authors / joe-ganley

Joe Ganley is vice president, government and regulatory affairs at athenahealth in Wellesley, Massachusetts.

Articles

Let’s Stop Talking About Interoperability and Just Make it Work

Let’s Stop Talking About Interoperability and Just Make it Work

Joe Ganley
April 24th 2023

Interoperability was theme at the Healthcare Information and Management Systems Society (HIMSS) meeting last week in Chicago. How can all that talk and aspiration be turned into action?

Read More

The Signals on Data Privacy Are Mixed. Healthcare's Future Depends on Which Ones Are Listened To.

The Signals on Data Privacy Are Mixed. Healthcare's Future Depends on Which Ones Are Listened To.

Joe Ganley
April 20th 2022

Big tech and its access to our data is a juicy target. But policy makers need to be careful or they will upend interoperability and turn back the clock on American healthcare.

Read More

Latest Updated Articles

Gaps in Diabetes Patient Education and Rising Healthcare Costs
Published: February 25th 2025 | Updated: February 28th 2025
Gaps in Diabetes Patient Education and Rising Healthcare Costs
black and white image of solders in jungle setting | ©daniel stock.adobe.com
Published: February 16th 2025 | Updated: February 19th 2025
Many Aging Vietnam War Vets Are Still Battling PTSD, Along With Chronic Illnesses, That Combat Exposure May Make More Likely, New Research Finds
food in heart shape with a stethoscope | image credit: ©udra11
Published: February 5th 2025 | Updated: February 7th 2025
A Key Ingredient to ‘Food is Medicine’: Standardization
Evernorth Drives Cigna's Strong Revenue Growth and Focuses on Biosimilars and Drug Affordability
Published: January 30th 2025 | Updated: January 31st 2025
Evernorth Drives Cigna's Strong Revenue Growth and Focuses on Biosimilars and Drug Affordability
The future of diabetes management: expanding access to and impact of CGM for patients with type 2 diabetes
Published: July 16th 2025 | Updated: July 30th 2025
The future of diabetes management: expanding access to and impact of CGM for patients with type 2 diabetes
For GLP-1s and Biosimilars, Some Celebration, Some Concern, Survey Finds | MHE 2025 Pharmacy Survey, Part 3
Published: May 20th 2025 | Updated: July 30th 2025
For GLP-1s and Biosimilars, Some Celebration, Some Concern, Survey Finds | MHE 2025 Pharmacy Survey, Part 3
© 2025 MJH Life Sciences

All rights reserved.